A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia

Author:  ["Tiziana Borsello","Peter G H Clarke","Lorenz Hirt","Alessandro Vercelli","Mariaelena Repici","Daniel F Schorderet","Julien Bogousslavsky","Christophe Bonny"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to activate the c-Jun N-terminal kinase (JNK) pathway. We have evaluated the neuroprotective power of a cell-penetrating, protease-resistant peptide that blocks the access of JNK to many of its targets. We obtained strong protection in two models of middle cerebral artery occlusion (MCAO): transient occlusion in adult mice and permanent occlusion in 14-d-old rat pups. In the first model, intraventricular administration as late as 6 h after occlusion reduced the lesion volume by more than 90% for at least 14 d and prevented behavioral consequences. In the second model, systemic delivery reduced the lesion by 78% and 49% at 6 and 12 h after ischemia, respectively. Protection correlated with prevention of an increase in c-Jun activation and c-Fos transcription. In view of its potency and long therapeutic window, this protease-resistant peptide is a promising neuroprotective agent for stroke.

Cite this article

Borsello, T., Clarke, P., Hirt, L. et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9, 1180–1186 (2003). https://doi.org/10.1038/nm911

View full text

>> Full Text:   A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia

L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload car

Clonal vaccinia virus grown in cell culture as a new smallpox vaccine